权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Clinical Core

临床核心

基本信息

批准号：
7575791
负责人：
Nezam Hassan Afdahl
金额：
$ 13.3万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-03-01 至 2010-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7575791
关键词：
AIDS clinical trial group Animal Model Basic Science Biometry Biopsy CD4 Lymphocyte Count Chronic Hepatitis C Cirrhosis Clinical Clinical Data Clinical Trials Cohort Studies Collaborations Complex Control Groups Databases Development Disease Disease Progression Egypt Etiology Evaluation Fibrosis Genotype HIV Hepatitis C virus Immunocompromised Host Immunology Individual Infection Lead Liver Liver Fibrosis Metabolic Molecular Mono-S Natural History Pathogenesis Pathology Patients Population Rate Recruitment Activity Recurrence Research Infrastructure Research Personnel Resources Retrospective Studies Risk Sampling Schistosomiasis Serum Specimen Staging Techniques Tissue Banks Tissues Transplantation Universities Validation Viral base cohort fibrogenesis follow-up human tissue liver biopsy liver transplantation metabolic abnormality assessment novel prevent repository response virology virus host interaction

项目摘要

The natural history of chronic HCV infection is very variable and retrospective studies have identified both slow progressors who take 40 years to develop cirrhosis and rapid progressors who may develop advanced fibrosis in as little as 10 - 20 years. The underlying pathophysiological mechanisms associated with disease progression are poorly understood and represent the central focus of this HCV Center. We will study cohorts of patients with variable rates of disease progression. The Clinical Center for HCV disease progression will provide liver tissues, specimens, clinical expertise, biostatistics and a pathology core to interact with the basic Investigators in this HCV Center proposal. The clinical center will utilize both existing cohorts and develop novel cohorts of patients with either slow or fast disease progression to study the underlying immunological, virological and metabolic factors associated with progression of liver fibrosis. In particular we will develop: 1) the Infrastructure for clinical investigation into mechanisms of disease progression and fibrosis in patients with HCV 2) Evaluation of 4 distinct cohorts of patients who have variable rates of fibrosis progression: A) Patients with HCV naive to treatment representing a control group of predominantly slow progressors B) Patients with HCV and Schistosomiasis who rapidly develop cirrhosis C) Patients with HIV/HCV; a subset of whom are immunocompromised with low CD4 counts and may progress more rapidly D) Patients post liver transplant who have recurrent HCV These studies may help identify the mechanism of fibrosis progression and lead to rational use of reources to identify and treat patients at higher risk of disease progression.

慢性HCV感染的自然史是非常多变的，回顾性研究已经确定了需要40年时间发展为肝硬化的缓慢进展者和可能在短短10 - 20年内发展为晚期纤维化的快速进展者。与疾病进展相关的潜在病理生理机制尚不清楚，这是本HCV中心关注的焦点。我们将研究具有不同疾病进展率的患者队列。HCV疾病进展临床中心将提供肝脏组织、标本、临床专业知识、生物统计学和病理学核心，以便与HCV疾病进展中心进行互动